The Asia Pacific Transcriptomics Market is expected to witness market growth of 8.3% CAGR during the forecast period (2021 2027).
Transcriptomics is the exploration of the transcriptome, which is the entire set of RNA transcripts produced by the genome under certain conditions or in a specific cell, utilizing high-throughput technologies like microarray analysis. In addition, genes that are differentially expressed in different cell groups or in response to different treatments can be identified by comparing transcriptomes.
Rising R&D spending in transcriptomic technologies by pharmaceutical and biotechnology companies, as well as increased demand for tailored medication in cancer treatment, are driving the growth of the RNA analysis/transcriptomics market. Additionally, Oxford Brookes University recognized the development of improved single-cell transcriptomic technologies in April 2021. These technologies evaluate several individual cells from living creatures and sequence each cell's genetic material. According to the study, this procedure allows scientists to swap samples between labs, maintain the material, and freeze sample sets to examine at the same time without harming the cell's quality.
Governments and businesses are increasing their funding for biotechnology research in Asia Pacific countries. In addition, the Japanese government and non-government groups are enthusiastic about the advancement of biotechnology research in Japan, and they sponsor research in health and the life sciences. This pushes scientists to go deeper into the transcriptomics field. Furthermore, the increased focus on Asia Pacific nations is likely to give growth prospects for manufacturers due to low-cost manufacturing services. Moreover, the leading players of the regional market have shifted their attention to emerging markets and begun to build a robust position in the market through various strategic efforts, such as acquisitions.
The growing applications of Transcriptomics in Human and pathogen transcriptomes is expected to boost its usage in the regional market. The majority of transcriptomic research has focused on either the host or the pathogen.
The China market dominated the Asia Pacific Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $705.9 million by 2027. The Japan market is anticipated to grow at a CAGR of 7.7% during (2021 - 2027). Additionally, The India market is expected to display a CAGR of 9% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Transcriptomics is the exploration of the transcriptome, which is the entire set of RNA transcripts produced by the genome under certain conditions or in a specific cell, utilizing high-throughput technologies like microarray analysis. In addition, genes that are differentially expressed in different cell groups or in response to different treatments can be identified by comparing transcriptomes.
Rising R&D spending in transcriptomic technologies by pharmaceutical and biotechnology companies, as well as increased demand for tailored medication in cancer treatment, are driving the growth of the RNA analysis/transcriptomics market. Additionally, Oxford Brookes University recognized the development of improved single-cell transcriptomic technologies in April 2021. These technologies evaluate several individual cells from living creatures and sequence each cell's genetic material. According to the study, this procedure allows scientists to swap samples between labs, maintain the material, and freeze sample sets to examine at the same time without harming the cell's quality.
Governments and businesses are increasing their funding for biotechnology research in Asia Pacific countries. In addition, the Japanese government and non-government groups are enthusiastic about the advancement of biotechnology research in Japan, and they sponsor research in health and the life sciences. This pushes scientists to go deeper into the transcriptomics field. Furthermore, the increased focus on Asia Pacific nations is likely to give growth prospects for manufacturers due to low-cost manufacturing services. Moreover, the leading players of the regional market have shifted their attention to emerging markets and begun to build a robust position in the market through various strategic efforts, such as acquisitions.
The growing applications of Transcriptomics in Human and pathogen transcriptomes is expected to boost its usage in the regional market. The majority of transcriptomic research has focused on either the host or the pathogen.
The China market dominated the Asia Pacific Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $705.9 million by 2027. The Japan market is anticipated to grow at a CAGR of 7.7% during (2021 - 2027). Additionally, The India market is expected to display a CAGR of 9% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- q PCR
- Microarrays
- Sequencing Technology
By Application
- Drug Discovery
- Diagnostics & Disease Profiling
- Others
By Component
- Consumables
- Instruments
- Software
- Services
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Transcriptomics Market by Technology
Chapter 5. Asia Pacific Transcriptomics Market by Application
Chapter 6. Asia Pacific Transcriptomics Market by Component
Chapter 7. Asia Pacific Transcriptomics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Methodology
LOADING...
